Shaopeng Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shaopeng Chen has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Yuyang Jiang
Guangdong Provincial Key Laboratory of Chinese Medicine Ingredients and Gut Microbiomics, School of Pharmacy, Shenzhen University Medical School
6 shared publications - Chunmei Gao
The Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China
5 shared publications - Yu Zong Chen
Tsinghua University
5 shared publications Chunyan Tan
The Guangdong Province Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; National & Local United Engineering Lab for Personalized Antitumor Drugs, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China
4 shared publicationsHao Cheng
4 shared publications- Zigao Yuan
Department of Chemistry, Tsinghua University, Beijing 100084, PR China; The Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China
4 shared publications
Latest Publications
- Open Access
- 10 January 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-13
8u, a pro-apoptosis/cell cycle arrest compound, suppresses invasion and metastasis through HSP90α downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells
8u, an acridine derivative, has been proved effective anti-hepatocarcinoma effect, while the underlying mechanism remains unclear. Here, metabolomics and proteomics approaches were applied to study its anti-cancer mechanism and explore its effect on HepG2 cells’ invasion and metastasis abilities. The results showed that 8u significantly suppressed HepG2 cells migration and enhanced cell-to-cell junctions. The inhibition effect of 8u on invasion and metastasis disappeared after HSP90α gene silencing, and was reversed after HSP90α overexpression. The biological experimental results indicated that 8u also blocked PI3K/Akt pathway, thereby reducing fatty acid synthase (FASN) protein expression and disordering intracellular lipid metabolism to inhibit cell invasion and metastasis. In addition, HSP90α protein and PI3K/Akt pathway could co-adjust to each other. These findings demonstrated that 8u could efficiently suppress the invasion and metastasis of HepG2 cells by decreasing the expression of HSP90α protein and inhibiting the PI3K/Akt signaling pathway, which could be used as a potential candidate for the treatment of HCC.
- 10 January 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-13
Open Access8u, a pro-apoptosis/cell cycle arrest compound, suppresses invasion and metastasis through HSP90α downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells
8u, an acridine derivative, has been proved effective anti-hepatocarcinoma effect, while the underlying mechanism remains unclear. Here, metabolomics and proteomics approaches were applied to study its anti-cancer mechanism and explore its effect on HepG2 cells’ invasion and metastasis abilities. The results showed that 8u significantly suppressed HepG2 cells migration and enhanced cell-to-cell junctions. The inhibition effect of 8u on invasion and metastasis disappeared after HSP90α gene silencing, and was reversed after HSP90α overexpression. The biological experimental results indicated that 8u also blocked PI3K/Akt pathway, thereby reducing fatty acid synthase (FASN) protein expression and disordering intracellular lipid metabolism to inhibit cell invasion and metastasis. In addition, HSP90α protein and PI3K/Akt pathway could co-adjust to each other. These findings demonstrated that 8u could efficiently suppress the invasion and metastasis of HepG2 cells by decreasing the expression of HSP90α protein and inhibiting the PI3K/Akt signaling pathway, which could be used as a potential candidate for the treatment of HCC.
- 1 September 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 138, 1135-1146
Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy
- 1 September 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 138, 1135-1146
Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy
- 1 August 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (15) , 4100-4109
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
- 1 August 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (15) , 4100-4109
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
- 1 August 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 136, 372-381
Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment
- 1 August 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 136, 372-381
Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment
- 1 July 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (13) , 3437-3446
Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors
- 1 July 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (13) , 3437-3446
Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors
- 1 July 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 134, 281-292
Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors
- 1 July 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 134, 281-292
Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors
- 1 January 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (1) , 27-37
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy
- 1 January 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (1) , 27-37
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy
- 3 June 2015
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 407 (1-2) , 57-68
AP4 activates cell migration and EMT mediated by p53 in MDA-MB-231 breast carcinoma cells
Tumor metastasis is the primary cause of mortality in most cancer patients. Before disassociation from the tumors, most of malignant tumor cells undergo the epithelial–mesenchymal transition to break away from the adhesions between the cells and the surrounding extracellular matrix. Recently, activating enhancer-binding protein (AP4) has been shown to be a mediator of EMT in colorectal cancer and high level of AP4 correlates with poor prognosis in cancer patients. It has been found that AP4 upregulates the genes involved in EMT and cell proliferation in colorectal cancer cells and that the aggressive human breast cancer cells MDA-MB-231 are highly metastatic. Therefore, we tested the hypothesis that AP4 may also affect cell migration and EMT in this cell type. Three different assays, including the wound-healing assay, the Boyden chamber assay, and the cell tracking assay, were employed to confirm that AP4 activated both cell migration and invasion. Immunofluorescence staining and Western blot analysis revealed that the cells underwent EMT when AP4 was upregulated. In contrast, overexpression of dominant-negative AP4, lacking the DNA-binding domain, inactivated the DNA-binding ability of endogenous AP4 and led to lower cell motility. Furthermore, we found that AP4 enhanced p53 expression at both transcriptional and translational levels. Knockdown of p53 by siRNA significantly diminished the activation of cell migration by AP4, indicating that AP4 can regulate cell migration via the activity of p53.
- 3 June 2015
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 407 (1-2) , 57-68
AP4 activates cell migration and EMT mediated by p53 in MDA-MB-231 breast carcinoma cells
Tumor metastasis is the primary cause of mortality in most cancer patients. Before disassociation from the tumors, most of malignant tumor cells undergo the epithelial–mesenchymal transition to break away from the adhesions between the cells and the surrounding extracellular matrix. Recently, activating enhancer-binding protein (AP4) has been shown to be a mediator of EMT in colorectal cancer and high level of AP4 correlates with poor prognosis in cancer patients. It has been found that AP4 upregulates the genes involved in EMT and cell proliferation in colorectal cancer cells and that the aggressive human breast cancer cells MDA-MB-231 are highly metastatic. Therefore, we tested the hypothesis that AP4 may also affect cell migration and EMT in this cell type. Three different assays, including the wound-healing assay, the Boyden chamber assay, and the cell tracking assay, were employed to confirm that AP4 activated both cell migration and invasion. Immunofluorescence staining and Western blot analysis revealed that the cells underwent EMT when AP4 was upregulated. In contrast, overexpression of dominant-negative AP4, lacking the DNA-binding domain, inactivated the DNA-binding ability of endogenous AP4 and led to lower cell motility. Furthermore, we found that AP4 enhanced p53 expression at both transcriptional and translational levels. Knockdown of p53 by siRNA significantly diminished the activation of cell migration by AP4, indicating that AP4 can regulate cell migration via the activity of p53.
- 1 May 2011
- Published by Elsevier in Chinese Chemical Letters
- Vol. 22 (5) , 505-507
Synthesis of (3S,4R)-bengamide E
- 1 May 2011
- Published by Elsevier in Chinese Chemical Letters
- Vol. 22 (5) , 505-507
Synthesis of (3S,4R)-bengamide E